Sign In
CPSI Share                                                                      
​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ ​​
Back to Search
Publication Type: Medication Safety Notice
Single or Multiple Incident: Multiple
Date: 4/1/2018 12:00:00 AM
Country: Australia
The purpose of this safety notice is to raise awareness of the availability of a new high concentration insulin product and provide information relevant to its safe use. Toujeo® (insulin glargine 300 units/mL) is a new high concentration insulin product, three times the concentration of standard insulin preparations (e.g. Lantus® 100 units/mL). It is only available in a pre-filled disposable pen device (Toujeo SoloStar®), and not in vials and must never be drawn up into a standard 100 unit/mL insulin syringe. The notice stresses that insulin syringes are calibrated for use with 100 units/mL insulin products. They cannot be used for higher concentration insulin products including Toujeo®. The notice provides recommended actions to prevent medication incidents with this new product.

Additional Details

Device:
pre-filled disposable pen device, Toujeo SoloStar®, Lantus SoloStar®
Medication/Gas/Fluid:
insulin, insulin glargine (Toujeo®, Lantus®)
Medication/IV List:
insulin, subcutaneous and IV

Rules / Policies / Procedures
  1. Do not use insulin syringes to administer high concentration insulins.
Training
  1. Be aware of the availability of high concentration insulin glargine 300 units/mL (Toujeo) and the likelihood that patients prescribed this medicine may be admitted to hospital.
  2. Ensure patients using a high concentration insulin at home have an individual plan developed to determine safe insulin management in hospital.

Insulin safety - High strength insulin glargine 300 units/mL